| Project/Area Number |
23655161
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Chemistry related to living body
|
|---|
| Research Institution | Osaka Prefecture University |
|---|
Principal Investigator |
FUJII Ikuo 大阪府立大学, 大学院・理学系研究科, 教授 (70189984)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUMURAYA Takeshi 大阪府立大学, 大学院・理学系研究科, 准教授 (00372855)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | ペプチド / 進化分子工学 / ファージライブラリー / 分子標的医薬 / 試験管内進化法 / 抗体 |
|---|
| Research Abstract |
Use of antibody medicines has been limited due to the biophysical properties, immunogenicity, non-cell permeability, high cost to manufacture, and so on. To enable new applications where antibodies showsome limitations, we have developed an alternative-binding molecule with non-immunoglobulin domain. The molecule is a helix- loop- helix peptide. In previous work, we constructed a phage-displayed library of the helix-loop-helix peptides and then screened the library for G-CSF receptor to obtain a molecular-targeting peptide. Here, we examined the ability of the binding peptide as an alternative to antibody medicines. The peptide showed strong binding affinity (K_d: 4 nM) to the receptor, an enzyme-resistant property(half-life: 15 days in mouse sera), and non-immunogenicity. This peptide is named “microAntibodes” due to having the same properties as those of antibodies. Furthermore, we examined to screen the library of helix-loop-helix peptides against VEGF to successfully gain a tight-binding peptide. The semi-rational strategy, which combines directed evolution with de novodesign, provides a new way to generate a post-antibody therapy.
|
